RecruitMe Clinical Trial

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimers Disease (MissionAD1)
MissionAD1: A 24-month Efficacy and Safety Study in Subjects with Early Alzheimer's Disease
Sponsor:EISAI
Enrolling:Male and Female Patients
Study Length:24 Months
Age Range:Between 50 and 85 years old
IRB Number:AAAR2556
U.S. Government ID:NCT02956486
Contact: Evelyn D. Dominguez: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information:

The name of this trial is MissionAD. This is a 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (AD), includingmild cognitive impairment (MCI) due to AD, known as Prodromal AD, and the early stages of mild AD.The study will be conducted to evaluate the efficacy and safety of E2609, whose proposed international nonproprietary name is elenbecestat.

This study is closed
Investigator
Lawrence Honig, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Evelyn D. Dominguez
Email: edd5@cumc.columbia.edu
Phone: 212-305-2371